Anti-tumor immunity induced by an anti-idiotype antibody mimicking human Her-2/neu

Kartik Mohanty, Asim Saha, Smarajit Pal, Palash Mallick, Sunil K. Chatterjee, Kenneth A. Foon, Malaya Bhattacharya-Chatterjee

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


Our goal is to apply an anti-idiotype (Id) antibody based vaccine approach for the treatment of Her-2/neu-positive human cancer. Amplification and/or over-expression of Her-2/neu occur in multiple human malignancies and are associated with poor prognosis. Her-2/neu proto-oncogene is a suitable target for cancer immunotherapy. We have developed and characterized a murine monoclonal anti-Id antibody, 6D12 that mimics a specific epitope of Her-2/neu and can be used as a surrogate antigen for Her-2/neu. In this study, the efficacy of 6D12 as a tumor vaccine was evaluated in a murine tumor model. Immunization of immunocompetent C57BL/6 mice with 6D12 conjugated to keyhole limpet hemocyanin and mixed with Freund's adjuvant or 6D12 combined with the adjuvant QS21 induced anti-6D12 as well as anti-Her-2/neu immunity. Her-2/neu-positive human breast carcinoma cells, SK-BR-3 reacted with immunized mice sera as determined by ELISA and flow cytometry. Flow cytometry analysis also demonstrated strong reactivity of immunized mice sera with human Her-2/neu transfected EL4 cells (EL4-Her-2), but no reactivity with nontransfected parental EL4 cells. Antibody dependent cellular cytotoxicity against EL4-Her-2 cells was also observed in presence of immune sera. Mice immunized with 6D12 were protected against a challenge with lethal doses of EL4-Her-2 cells, whereas no protection was observed against parental EL4 cells or when mice were immunized with an unrelated anti-Id antibody and challenged with EL4-Her-2 cells. These data suggest that anti-Id 6D12 vaccine can induce protective Her-2/neu specific antitumor immunity and may serve as a potential network antigen for the treatment of patients with Her-2/neu-positive tumors.

Original languageEnglish (US)
Pages (from-to)1-11
Number of pages11
JournalBreast Cancer Research and Treatment
Issue number1
StatePublished - Jul 2007

Bibliographical note

Funding Information:
Acknowledgements We would like to thank Dr. Joseph D. Rosenblatt (Department of Medicine, University of Miami School of Medicine, Miami, FL) for providing the EL4-Her-2 cells. We also like to thank Mary B. Palascak and Peter Ciraolo for help in flow cytometry. This work was supported by the NIH Grant RO1 CA91878.


  • Anti-idiotype antibody
  • Breast cancer
  • Her-2/neu
  • Murine model
  • Vaccines


Dive into the research topics of 'Anti-tumor immunity induced by an anti-idiotype antibody mimicking human Her-2/neu'. Together they form a unique fingerprint.

Cite this